Peptide Therapeutics Market
Analysts’ Viewpoint on Global Market Scenario
Sedentary lifestyle and unhealthy diet are leading to a surge in prevalence and incidence of chronic diseases. High incidence and prevalence of metabolic disorders is expected to drive the global market in the next few years. Growth in geriatric population across the globe is also expected to boost the global market for peptide therapeutics. Peptides are now being widely used in therapeutic applications of cancer and chronic metabolic diseases due to advancements in technology. Rise in prevalence of cancer among the geriatric population is anticipated to increase the demand for new peptide therapeutics. Industry players are investing in research and development activities to introduce new peptide therapeutics in order to address this peptide therapeutics market demand.
Peptides are a combination of two or more amino acid monomers linked by amide bonds. Researchers have demonstrated that peptides are distinguished from proteins on the basis of size. As a benchmark, molecules with less than 50 amino acids are considered peptides. In addition to the current definition of peptide, the FDA updated its definition of a biologic to include chemically synthesized polypeptides greater than 40 amino acids but less than 100 amino acids in size (synthetic proteins) and synthetic peptides 40 amino acids or less. Peptides bind to specific cell surface receptors and receptor ligands and help in the treatment of diseases by acting on the cell membrane. Therapeutic proteins and peptides are a growing class of drugs intended for clinical purposes owning to high bio-specificity. As per the peptide therapeutics industry analysis, demand for peptide therapeutics has been rising significantly due to the decline in non-peptide chemical drugs available in the market.
Request a sample to get extensive insights into the Peptide Therapeutics Market
The COVID-19 pandemic has had a positive impact on the global peptide therapeutics market growth. As of August 2022, 600 million infections and 6.4 million deaths were recorded across the world due to COVID-19. Peptide molecules are being used for the development of the COVID-19 vaccine. Furthermore, government authorities of various countries have supported private players in the development and usage of the COVID-19 vaccine. More than 21 peptide drugs are being used for the treatment of COVID-19, including 15 synthetic peptides in development for the treatment of acute respiratory distress syndrome (ARDS) and other respiratory illnesses caused by SARS-Cov-2 infection. Peptide drugs are being considered a treatment option for COVID-19. Thus, key players in the market have reported an increase in revenue during the COVID-19 pandemic. However, the application of peptide therapeutics in oncology, metabolic disorders, etc. has been disrupted due to a shortage of drugs and supply chain issues along with the slow progress of clinical trials related to non-COVID-19 therapeutics.
In terms of application, the cancer segment dominated the global market in 2021. Cancer is the leading cause of death globally. According to the World Health Organization, cancer accounted for nearly 10 million deaths globally in 2020. Chemotherapy, the major mode of treatment for cancer, is facing major challenges due to its inability to deliver the correct amount of drug directly, which negatively affects the normal cells in the body. The application of therapeutic peptides in cancer treatment has opened a promising avenue for future growth of the global peptide therapeutics business, as it has the ability to deliver drugs with specific binding sites. Peptide-based therapeutic vaccines have attracted attention as one of the most effective treatments for tumor immunotherapy over the last few years. A rise in the prevalence and incidence rate of other chronic conditions such as Alzheimer's, diabetes, cardiac diseases, and immune disorders, owing to the increase in the geriatric population, is projected to propel the global peptide and Alzheimer's peptide therapeutics markets in the next few years.
Request a custom report on Peptide Therapeutics Market
Based on the route of administration, the global peptide therapeutics industry has been classified into parenteral, oral, and others. The parenteral segment dominated the global market in 2021. Parenteral is the most common route of administration, as it ensures faster and better bioavailability, faster onset time, and better treatment outcomes. However, advancement in drug delivery technologies has led to a change in the trend of the route of administration of therapeutic peptides.
Based on technology, the liquid phase segment held the largest share of the global peptide therapeutics market in 2021. Liquid phase synthesis is usually favored for peptides, which have less than 15 amino acids in length. Liquid-phase peptide synthesis provides economies of scale for the manufacturing of peptides. Minimal waste and high peptide purity and yield are the key advantages of this technology.
In terms of the type of molecule, the immunopeptide segment is likely to grow at a rapid pace during the forecast period owing to the rise in the usage of immunopeptides in drugs for the treatment of cancer and tumors. The high prevalence of cancer and the surge in the incidence rate of new cancer cases are likely to drive the immunopeptides segment during the forecast period.
Based on the API peptide type, the in-house segment dominated the global market in 2021. However, API manufacturers prefer to outsource peptide manufacturing to contract manufacturing organizations (CMOs) operating in the biosimilar market due to difficulties in manufacturing owing to the high-quality standards implemented by regulatory authorities. For instance, Bachem and Peptisyntha provide end-to-end API peptide manufacturing and possess the expertise and high-end technology for various types of peptides. Nevertheless, the shift is likely to be gradual, as most API peptide companies still prefer to manufacture in-house due to stringent quality systems and standards requirements.
North America is projected to dominate the global market for peptide therapeutics during the forecast period. Well-established healthcare infrastructure, high-priced peptide therapeutics drugs, and favorable reimbursement policies are augmenting the peptide therapeutics market growth in the region.
The market in Asia Pacific is anticipated to grow at a high CAGR during the forecast period due to the rise in the prevalence of infectious diseases in the region. The increase in the geriatric population and surge in healthcare expenditure are fueling the market in the Asia Pacific. Furthermore, a large patient pool and high demand for newer advanced therapies are key factors likely to boost the market for peptide therapeutics in Asia Pacific.
The peptide therapeutics market report includes vital information about leading players in the global market. Companies are adopting product launches, divestitures, mergers & acquisitions, and partnership strategies to enhance their peptide therapeutics industry share. Amgen, Inc., Bachem Holding AG, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Novartis AG, Pfizer, Inc., Sanofi, Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd. are the prominent players operating in the global market.
Each of these players has been profiled in the peptide therapeutics market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
|
Attribute |
Detail |
|
Market Size Value in 2021 |
US$ 39.34 Bn |
|
Market Forecast Value in 2031 |
More than US$ 91.25 Bn |
|
Growth Rate (CAGR) for 2022–2031 |
8.8% |
|
Forecast Period |
2022–2031 |
|
Historical Data Available for |
2017–2021 |
|
Quantitative Units |
US$ Bn for Value |
|
Market Analysis |
It includes segment analysis as well as regional-level analysis. Moreover, the qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Market Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
The global market for peptide therapeutics is to expand at a CAGR of 8.8% from 2022 to 2031
The Peptide therapeutics market is driven by a rise in the adoption of hybrid technologies to achieve their economies of scale
North America accounted for a major share of the global market
The cancer segment held the highest share on account of its increasing prevalence all across the world
Key players in the global market for peptide therapeutics include Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Sanofi, Pfizer Inc., Novartis AG, GlaxoSmithKline plc., F.Hoffmann-La Roche Ltd.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Peptide Therapeutics Market
4. Market Overview
4.1. Introduction
4.1.1. Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Peptide Therapeutics Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. White Space Analysis
5.2. Porter’s Analysis
5.3. Pipeline Analysis (Phase III)
5.4. Peptide Drug Chemical Structure Trend Analysis
5.5. Separation Media for Peptide Drug Manufacturing
5.6. Covid-19 Impact Analysis
6. Global Peptide Therapeutics Market Analysis and Forecast, by Application
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Application, 2017–2031
6.3.1. Cancer
6.3.2. Metabolic
6.3.3. CVD
6.3.4. Respiratory
6.3.5. GIT
6.3.6. Anti-infective
6.3.7. Dermatology
6.3.8. CNS
6.3.9. Renal
6.4. Market Attractiveness Analysis, by Application
7. Global Peptide Therapeutics Market Analysis and Forecast, by Route of Administration
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Route of Administration, 2017–2031
7.3.1. Parenteral
7.3.2. Oral
7.4. Market Attractiveness Analysis, by Route of Administration
8. Global Peptide Therapeutics Market Analysis and Forecast, by Type
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Type, 2017–2031
8.3.1. Innovative
8.3.2. Generic
8.4. Market Attractiveness Analysis, by Type
9. Global Peptide Therapeutics Market Analysis and Forecast, by Technology
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by Technology, 2017–2031
9.3.1. Liquid Phase
9.3.2. Solid Phase
9.3.3. Hybrid Phase
9.4. Market Attractiveness Analysis, by Technology
10. Global Peptide Therapeutics Market Analysis and Forecast, by Type of Molecule
10.1. Introduction & Definition
10.2. Key Findings / Developments
10.3. Market Value Forecast, by Type of Molecule, 2017–2031
10.3.1. Vasopressin
10.3.2. Somatostatin
10.3.3. Calcitonin
10.3.4. Natriuretic
10.4. Market Attractiveness Analysis, by Type of Molecule
11. Global Peptide Therapeutics Market Analysis and Forecast, by API Peptide Type
11.1. Introduction & Definition
11.2. Key Findings / Developments
11.3. Market Value Forecast, by API Peptide Type ,2017–2031
11.3.1. In-house
11.3.2. CMO
11.4. Market Attractiveness Analysis, by API Peptide Type
12. Global Peptide Therapeutics Market Analysis and Forecast, by Region
12.1. Key Findings
12.2. Market Value Forecast, by Region
12.2.1. North America
12.2.2. Europe
12.2.3. Asia Pacific
12.2.4. Latin America
12.2.5. Middle East & Africa
12.3. Market Attractiveness Analysis, by Region
13. North America Peptide Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Application,2017–2031
13.2.1. Cancer
13.2.2. Metabolic
13.2.3. CVD
13.2.4. Respiratory
13.2.5. GIT
13.2.6. Anti-infective
13.2.7. Dermatology
13.2.8. CNS
13.2.9. Renal
13.3. Market Value Forecast, by End-user,2017–2031
13.3.1. Parenteral
13.3.2. Oral
13.4. Market Value Forecast, by Type, 2017–2031
13.4.1. Innovative
13.4.2. Generic
13.5. Market Value Forecast, by Technology, 2017–2031
13.5.1. Liquid Phase
13.5.2. Solid Phase
13.5.3. Hybrid Phase
13.6. Market Value Forecast, by Type of Molecule, 2017–2031
13.6.1. Vasopressin
13.6.2. Somatostatin
13.6.3. Calcitonin
13.6.4. Natriuretic
13.7. Market Value Forecast, by API Peptide Type, 2017–2031
13.7.1. In-house
13.7.2. CMO
13.8. Market Value Forecast, by Country, 2017–2031
13.8.1. U.S.
13.8.2. Canada
13.9. Market Attractiveness Analysis
13.9.1. By Application
13.9.2. By Route of Administration
13.9.3. By Type
13.9.4. By Technology
13.9.5. By Type of Molecule
13.9.6. By API Peptide Type
13.9.7. By Country
14. Europe Peptide Therapeutics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Application, 2017–2031
14.2.1. Cancer
14.2.2. Metabolic
14.2.3. CVD
14.2.4. Respiratory
14.2.5. GIT
14.2.6. Anti-infective
14.2.7. Dermatology
14.2.8. CNS
14.2.9. Renal
14.3. Market Value Forecast, by End-user, 2017–2031
14.3.1. Parenteral
14.3.2. Oral
14.4. Market Value Forecast, by Type, 2017–2031
14.4.1. Innovative
14.4.2. Generic
14.5. Market Value Forecast, by Technology, 2017–2031
14.5.1. Liquid Phase
14.5.2. Solid Phase
14.5.3. Hybrid Phase
14.6. Market Value Forecast, by Type of Molecule, 2017–2031
14.6.1. Vasopressin
14.6.2. Somatostatin
14.6.3. Calcitonin
14.6.4. Natriuretic
14.7. Market Value Forecast, by API Peptide Type, 2017–2031
14.7.1. In-house
14.7.2. CMO
14.8. Market Value Forecast, by Country/Sub-region, 2017–2031
14.8.1. Germany
14.8.2. U.K.
14.8.3. France
14.8.4. Spain
14.8.5. Italy
14.8.6. Rest of Europe
14.9. Market Attractiveness Analysis
14.9.1. By Application
14.9.2. By Route of Administration
14.9.3. By Type
14.9.4. By Technology
14.9.5. By Type of Molecule
14.9.6. By API Peptide Type
14.9.7. By Country/Sub-region
15. Asia Pacific Peptide Therapeutics Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Application, 2017–2031
15.2.1. Cancer
15.2.2. Metabolic
15.2.3. CVD
15.2.4. Respiratory
15.2.5. GIT
15.2.6. Anti-infective
15.2.7. Dermatology
15.2.8. CNS
15.2.9. Renal
15.3. Market Value Forecast, by End-user, 2017–2031
15.3.1. Parenteral
15.3.2. Oral
15.4. Market Value Forecast, by Type, 2017–2031
15.4.1. Innovative
15.4.2. Generic
15.5. Market Value Forecast, by Technology, 2017–2031
15.5.1. Liquid Phase
15.5.2. Solid Phase
15.5.3. Hybrid Phase
15.6. Market Value Forecast, by Type of Molecule, 2017–2031
15.6.1. Vasopressin
15.6.2. Somatostatin
15.6.3. Calcitonin
15.6.4. Natriuretic
15.7. Market Value Forecast, by API Peptide Type, 2017–2031
15.7.1. In-house
15.7.2. CMO
15.8. Market Value Forecast, by Country/Sub-region, 2017–2031
15.8.1. China
15.8.2. Japan
15.8.3. India
15.8.4. Australia & New Zealand
15.8.5. Rest of Asia Pacific
15.9. Market Attractiveness Analysis
15.9.1. By Application
15.9.2. By Route of Administration
15.9.3. By Type
15.9.4. By Technology
15.9.5. By Type of Molecule
15.9.6. By API Peptide Type
15.9.7. By Country/Sub-region
16. Latin America Peptide Therapeutics Market Analysis and Forecast
16.1. Introduction
16.1.1. Key Findings
16.2. Market Value Forecast, by Application, 2017–2031
16.2.1. Cancer
16.2.2. Metabolic
16.2.3. CVD
16.2.4. Respiratory
16.2.5. GIT
16.2.6. Anti-infective
16.2.7. Dermatology
16.2.8. CNS
16.2.9. Renal
16.3. Market Value Forecast, by End-user, 2017–2031
16.3.1. Parenteral
16.3.2. Oral
16.4. Market Value Forecast, by Type, 2017–2031
16.4.1. Innovative
16.4.2. Generic
16.5. Market Value Forecast, by Technology,2017–2031
16.5.1. Liquid Phase
16.5.2. Solid Phase
16.5.3. Hybrid Phase
16.6. Market Value Forecast, by Type of Molecule, 2017–2031
16.6.1. Vasopressin
16.6.2. Somatostatin
16.6.3. Calcitonin
16.6.4. Natriuretic
16.7. Market Value Forecast, by API Peptide Type, 2017–2031
16.7.1. In-house
16.7.2. CMO
16.8. Market Value Forecast, by Country/Sub-region, 2017–2031
16.8.1. Brazil
16.8.2. Mexico
16.8.3. Rest of Latin America
16.9. Market Attractiveness Analysis
16.9.1. By Application
16.9.2. By Route of Administration
16.9.3. By Type
16.9.4. By Technology
16.9.5. By Type of Molecule
16.9.6. By API Peptide Type
16.9.7. By Country/Sub-region
17. Middle East & Africa Peptide Therapeutics Market Analysis and Forecast
17.1. Introduction
17.1.1. Key Findings
17.2. Market Value Forecast, by Application, 2017–2031
17.2.1. Cancer
17.2.2. Metabolic
17.2.3. CVD
17.2.4. Respiratory
17.2.5. GIT
17.2.6. Anti-infective
17.2.7. Dermatology
17.2.8. CNS
17.2.9. Renal
17.3. Market Value Forecast, by End-user, 2017–2031
17.3.1. Parenteral
17.3.2. Oral
17.4. Market Value Forecast, by Type, 2017–2031
17.4.1. Innovative
17.4.2. Generic
17.5. Market Value Forecast, by Technology, 2017–2031
17.5.1. Liquid Phase
17.5.2. Solid Phase
17.5.3. Hybrid Phase
17.6. Market Value Forecast, by Type of Molecule, 2017–2031
17.6.1. Vasopressin
17.6.2. Somatostatin
17.6.3. Calcitonin
17.6.4. Natriuretic
17.7. Market Value Forecast, by API Peptide Type, 2017–2031
17.7.1. In-house
17.7.2. CMO
17.8. Market Value Forecast, by Country/Sub-region, 2017–2031
17.8.1. GCC Countries
17.8.2. South Africa
17.8.3. Rest of Middle East & Africa
17.9. Market Attractiveness Analysis
17.9.1. By Application
17.9.2. By Route of Administration
17.9.3. By Type
17.9.4. By Technology
17.9.5. By Type of Molecule
17.9.6. By API Peptide Type
17.9.7. By Country/Sub-region
18. Competition Landscape
18.1. Market Player – Competition Matrix (by tier and size of companies)
18.2. Market Share Analysis, by Company, 2021
18.3. Company Profiles
18.3.1. Amgen, Inc.
18.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.1.2. Product Portfolio
18.3.1.3. SWOT Analysis
18.3.1.4. Strategic Overview
18.3.2. Bachem Holding AG
18.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.2.2. Product Portfolio
18.3.2.3. SWOT Analysis
18.3.2.4. Strategic Overview
18.3.3. Eli Lilly and Company
18.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.3.2. Product Portfolio
18.3.3.3. SWOT Analysis
18.3.3.4. Strategic Overview
18.3.4. F. Hoffmann-La Roche Ltd.
18.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.4.2. Product Portfolio
18.3.4.3. SWOT Analysis
18.3.4.4. Strategic Overview
18.3.5. GlaxoSmithKline plc
18.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.5.2. Product Portfolio
18.3.5.3. SWOT Analysis
18.3.5.4. Strategic Overview
18.3.6. Novartis AG
18.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.6.2. Product Portfolio
18.3.6.3. SWOT Analysis
18.3.6.4. Strategic Overview
18.3.7. Pfizer, Inc.
18.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.7.2. Product Portfolio
18.3.7.3. SWOT Analysis
18.3.7.4. Strategic Overview
18.3.8. Sanofi
18.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.8.2. Product Portfolio
18.3.8.3. SWOT Analysis
18.3.8.4. Strategic Overview
18.3.9. Takeda Pharmaceutical Company Limited
18.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.9.2. Product Portfolio
18.3.9.3. SWOT Analysis
18.3.9.4. Strategic Overview
18.3.10. Teva Pharmaceutical Industries Ltd.
18.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.10.2. Product Portfolio
18.3.10.3. SWOT Analysis
18.3.10.4. Strategic Overview
List of Table
Table 01: Global Peptide Therapeutics Market Size (US$ Mn) Forecast, by Application, 2021–2031
Table 02: Global Peptide Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2021–2031
Table 03: Global Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type, 2021–2031
Table 04: Global Peptide Therapeutics Market Size (US$ Mn) Forecast, by Technology, 2021–2031
Table 05: Global Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type of Molecule, 2021–2031
Table 06: Global API Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type, 2021–2031
Table 07: Global Peptide Therapeutics Market Size (US$ Mn) Forecast, by Region, 2021–2031
Table 08: North America Peptide Therapeutics Market Size (US$ Mn) Forecast, by Country, 2021–2031
Table 09: North America Peptide Therapeutics Market Size (US$ Mn) Forecast, by Application, 2021–2031
Table 10: North America Peptide Therapeutics Market Size (US$) Forecast, by Route of Administration, 2021–2031
Table 11: North America Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type, 2021–2031
Table 12: North America Peptide Therapeutics Market Size (US$ Mn) Forecast, by Technology, 2021–2031
Table 13: North America Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type of Molecule, 2021–2031
Table 14: North America API Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type, 2021–2031
Table 15: Europe Peptide Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2021–2031
Table 16: Europe Peptide Therapeutics Market Size (US$ Mn) Forecast, by Application, 2021–2031
Table 17: Europe Peptide Therapeutics Market Size (US$) Forecast, by Route of Administration, 2021–2031
Table 18: Europe Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type, 2021–2031
Table 19: Europe Peptide Therapeutics Market Size (US$ Mn) Forecast, by Technology, 2021–2031
Table 20: Europe Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type of Molecule, 2021–2031
Table 21: Europe API Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type, 2021–2031
Table 22: Asia Pacific Peptide Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2021–2031
Table 23: Asia Pacific Peptide Therapeutics Market Size (US$ Mn) Forecast, by Application, 2021–2031
Table 24: Asia Pacific Peptide Therapeutics Market Size (US$) Forecast, by Route of Administration, 2021–2031
Table 25: Asia Pacific Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type, 2021–2031
Table 26: Asia Pacific Peptide Therapeutics Market Size (US$ Mn) Forecast, by Technology, 2021–2031
Table 27: Asia Pacific Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type of Molecule, 2021–2031
Table 28: Asia Pacific API Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type, 2021–2031
Table 29: Latin America Peptide Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2021–2031
Table 30: Latin America Peptide Therapeutics Market Size (US$ Mn) Forecast, by Application, 2021–2031
Table 31: Latin America Peptide Therapeutics Market Size (US$) Forecast, by Route of Administration, 2021–2031
Table 32: Latin America Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type, 2021–2031
Table 33: Latin America Peptide Therapeutics Market Size (US$ Mn) Forecast, by Technology, 2021–2031
Table 34: Latin America Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type of Molecule, 2021–2031
Table 35: Latin America API Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type, 2021–2031
Table 36: Middle East & Africa Peptide Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2021–2031
Table 37: Middle East & Africa Peptide Therapeutics Market Size (US$ Mn) Forecast, by Application, 2021–2031
Table 38: Middle East & Africa Peptide Therapeutics Market Size (US$) Forecast, by Route of Administration, 2021–2031
Table 39: Middle East & Africa Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type, 2021–2031
Table 40: Middle East & Africa Peptide Therapeutics Market Size (US$ Mn) Forecast, by Technology, 2021–2031
Table 41: Middle East & Africa Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type of Molecule, 2021–2031
Table 42: Middle East & Africa API Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type, 2021–2031
List of Figures
Figure 01: Global Peptide Therapeutics Market Value Share Analysis, by Application, 2021 and 2031
Figure 02: Global Cancer Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031
Figure 03: Global Metabolic Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031
Figure 04: Global CVD Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031
Figure 05: Global Respiratory Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031
Figure 06: Global GIT Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031
Figure 07: Global Anti-infective Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031
Figure 08: Global Dermatology Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031
Figure 09: Global CNS Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031
Figure 10: Global Renal Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031
Figure 11: Global Others Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031
Figure 12: Global Peptide Therapeutics Market Attractiveness Analysis, by Application, 2022–2031
Figure 13: Global Peptide Therapeutics Market Value Share Analysis, by Route of Administration, 2021 and 2031
Figure 14: Global Peptide Therapeutics Market Size (US$ Mn) Forecast, by Parenteral, 2021–2031
Figure 15: Global Peptide Therapeutics Market Size (US$ Mn) Forecast, by Oral, 2021–2031
Figure 16: Global Peptide Therapeutics Market Size (US$ Mn) Forecast, by Others, 2021–2031
Figure 17: Global Peptide Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022–2031
Figure 18: Global Peptide Therapeutics Market Value Share Analysis, by Type, 2021 and 2031
Figure 19: Global Innovative Peptide Therapeutics Market Size (US$ Mn), 2021–2031
Figure 20: Global Generic Peptide Therapeutics Market Size (US$ Mn), 2021–2031
Figure 21: Global Peptide Therapeutics Market Attractiveness Analysis, by Type, 2022–2031
Figure 21: Global Peptide Therapeutics Market Value Share Analysis, by Technology, 2021 and 2031
Figure 22: Global Liquid Phase Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031
Figure 23: Global Solid Phase Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031
Figure 24: Global Hybrid Phase Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031
Figure 25: Global Peptide Therapeutics Market Attractiveness Analysis, by Technology, 2022–2031
Figure 26: Global Peptide Therapeutics Market Value Share Analysis, by Type of Molecules, 2021 and 2031
Figure 27: Global Vasopressin Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031
Figure 28: Global Somatostatins Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031
Figure 29: Global Calcitonin Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031
Figure 30: Global Immunopeptides Therapeutics Market Size Forecast (US$ Mn), 2021–2031
Figure 31: Global Natriuretic Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031
Figure 32: Global Other Peptides Therapeutics Market Size Forecast (US$ Mn), 2021–2031
Figure 33: Global Peptide Therapeutics Market Attractiveness Analysis, by Type of Molecule, 2022–2031
Figure 34: Global API Peptide Therapeutics Market Value Share Analysis, by Type, 2021 and 2031
Figure 35: Global In-house Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031
Figure 36: Global CMO Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031
Figure 37: Global API Peptide Therapeutics Market Attractiveness Analysis, by Type, 2022–2031
Figure 38: North America Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031
Figure 39: Europe Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031
Figure 40: Asia Pacific Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031
Figure 41: Latin America Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031
Figure 42: MEA Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031
Figure 43: Global Peptide Therapeutics Market Attractiveness Analysis, by Region, 2022–2031
Figure 44: U.S. Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031
Figure 45: Canada Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031
Figure 46: North America Peptide Therapeutics Market Attractiveness Analysis, by Country, 2022–2031
Figure 47: North America Peptide Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022–2031
Figure 48: North America Peptide Therapeutics Market Attractiveness Analysis, by Type, 2022–2031
Figure 49: North America Peptide Therapeutics Market Attractiveness Analysis, by Technology, 2022–2031
Figure 50: Germany Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031
Figure 51: U.K. Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031
Figure 52: France Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031
Figure 53: Italy Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031
Figure 54: Spain Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031
Figure 55: Rest of Europe Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031
Figure 56: Europe Peptide Therapeutics Market Attractiveness Analysis, by Country, 2022–2031
Figure 57: Europe Peptide Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022–2031
Figure 58: Europe Peptide Therapeutics Market Attractiveness Analysis, by Type, 2022–2031
Figure 59: Europe Peptide Therapeutics Market Attractiveness Analysis, by Technology, 2022–2031
Figure 60: Japan Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031
Figure 61: China Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031
Figure 62: India Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031
Figure 63: Rest of APAC Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031
Figure 64: Asia Pacific Peptide Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 65: Asia Pacific Peptide Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022–2031
Figure 66: Asia Pacific Peptide Therapeutics Market Attractiveness Analysis, by Type, 2022–2031
Figure 67: Asia Pacific Peptide Therapeutics Market Attractiveness Analysis, by Technology, 2022–2031
Figure 68: Brazil Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031
Figure 69: Mexico Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031
Figure 70: Rest of LATAM Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031
Figure 71: Latin America Peptide Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 72: Latin America Peptide Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022–2031
Figure 73: Latin America Peptide Therapeutics Market Attractiveness Analysis, by Type, 2022–2031
Figure 74: Latin America Peptide Therapeutics Market Attractiveness Analysis, by Technology, 2022–2031
Figure 75: South Africa Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031
Figure 76: Saudi Arabia Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031
Figure 77: Rest of MEA Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031
Figure 78: Middle East & Africa Peptide Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 79: Middle East & Africa Peptide Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022–2031
Figure 80: Middle East & Africa Peptide Therapeutics Market Attractiveness Analysis, by Type, 2022–2031
Figure 81: Middle East & Africa Peptide Therapeutics Market Attractiveness Analysis, by Technology, 2022–2031
Figure 82: Peptide Therapeutics Market Share Analysis, by Company, 2021
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
*86 figures and 60 tables includes